FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE Drug Patent Profile

✉ Email this page to a colleague

When do Fosinopril Sodium And Hydrochlorothiazide patents expire, and when can generic versions of Fosinopril Sodium And Hydrochlorothiazide launch?

Fosinopril Sodium And Hydrochlorothiazide is a drug marketed by Ani Pharms, Aurobindo Pharma, Avet Lifesciences, Invagen Pharms, Mylan, Sandoz, Sun Pharm Inds Ltd, and Teva. and is included in nine NDAs.

The generic ingredient in FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE is fosinopril sodium; hydrochlorothiazide. There are six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the fosinopril sodium; hydrochlorothiazide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Fosinopril Sodium And Hydrochlorothiazide

A generic version of FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE was approved as fosinopril sodium; hydrochlorothiazide by SANDOZ on September 28^th, 2005.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE?
What are the global sales for FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE?
What is Average Wholesale Price for FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE?

Summary for FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

US Patents:	0
Applicants:	8
NDAs:	9
Finished Product Suppliers / Packagers:	2
Clinical Trials:	2
DailyMed Link:	FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE at DailyMed

Drug patent expirations by year for FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

Recent Clinical Trials for FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Ranbaxy Laboratories Limited	N/A

See all FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE clinical trials

Pharmacology for FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

Drug Class	Angiotensin Converting Enzyme Inhibitor Thiazide Diuretic
Mechanism of Action	Angiotensin-converting Enzyme Inhibitors
Physiological Effect	Increased Diuresis

US Patents and Regulatory Information for FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ani Pharms	FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE	fosinopril sodium; hydrochlorothiazide	TABLET;ORAL	076608-001	Dec 3, 2004		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Teva	FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE	fosinopril sodium; hydrochlorothiazide	TABLET;ORAL	076945-002	Jul 5, 2006		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Avet Lifesciences	FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE	fosinopril sodium; hydrochlorothiazide	TABLET;ORAL	079025-001	Sep 17, 2010		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Ani Pharms	FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE	fosinopril sodium; hydrochlorothiazide	TABLET;ORAL	077144-002	Aug 16, 2005		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

AI Research Assistant

Questions you can ask:

Summary for FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

Recent Clinical Trials for FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

Pharmacology for FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

Make Better Decisions: Try a trial or see plans & pricing